Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction

Circulation Journal

Volumn 77, Issue 9, 2013, Pages 2366-2374

  Efthimiadis, Georgios K ^a   Pagourelias, Efstathios D ^a   Parcharidou, Despoina ^a   Gossios, Thomas ^a   Kamperidis, Vasileios ^a   Theoflogiannakos, Efstratios K ^a   Pappa, Zoi ^a   Meditskou, Soultana ^b   Hadjimiltiades, Stavros ^a   Pliakos, Christodoulos ^a   Karvounis, Haralampos ^a   Styliadis, Ioannis H ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Heart failure; Hypertrophic cardiomyopathy; Midventricular obstruction; Sudden death

Indexed keywords

ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; DISOPYRAMIDE; VERAPAMIL; WARFARIN;

ADULT; ANEURYSM; ARTICLE; DISEASE COURSE; ECHOCARDIOGRAPHY; FAINTNESS; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART OUTFLOW TRACT OBSTRUCTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MIDVENTRICULAR OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; SUDDEN DEATH; SURVIVAL;

CARDIOMYOPATHY, HYPERTROPHIC; VENTRICULAR OUTFLOW OBSTRUCTION; ADULT; AGED; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84882761180     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1561     Document Type: Article

References (27)

1. Otsuka H, Arimura T, Abe T, Kawai H, Aizawa Y, Kubo T, et al. Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. Circ J 2012; 76: 453-461.
2. Kubo T, Kitaoka H, Okawa M, Baba Y, Hirota T, Hayato K, et al. Genetic screening and double mutation in Japanese patients with hy-pertrophic cardiomyopathy. Circ J 2011; 75: 2654-2659.
3. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiog-raphy, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angi-ography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58: e212-e260, doi:10.1016/j.jacc.2011.06.011 (accessed December 14, 2012).
4. Falicov RE, Resnekov L, Bharati S, Lev M. Mid-ventricular obstruction: A variant of obstructive cardiomyopathy. Am J Cardiol 1976; 37: 432-437.
5. Falicov RE, Resnekov L. Midventricular obstruction in hypertrophic obstructive cardiomyopathy: New diagnostic and therapeutic challenge. Br Heart J 1977; 39: 701-705.
6. Blazer D, Kotler MN, Parry WR, Wertheimer J, Nakhjavan FK. Noninvasive evaluation of mid-left ventricular obstruction by two-dimensional and Doppler echocardiography and color fow Doppler echocardiography. Am Heart J 1987; 114: 1162-1168.
7. Tse HF, Ho HH. Sudden cardiac death caused by hypertrophic car-diomyopathy associated with midventricular obstruction and apical aneurysm. Heart 2003; 89: 178.
8. Efthimiadis GK, Giannakoulas G, Parcharidou DG, Ziakas AG, Papadopoulos CE, Karoulas T, et al. Subaortic and midventricular obstructive hypertrophic cardiomyopathy with extreme segmental hypertrophy. Cardiovasc Ultrasound 2007; 5: 12.
9. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, et al. Prevalence, clinical signifcance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118: 1541-1549.
10. Efthimiadis GK, Pliakos C, Pagourelias ED, Parcharidou DG, Spanos G, Paraskevaidis S, et al. Hypertrophic cardiomyopathy with midven-tricular obstruction and apical aneurysm formation in a single family: Case report. Cardiovasc Ultrasound 2009; 7: 26.
11. Shah A, Duncan K, Winson G, Chaudhry FA, Sherrid MV. Severe symptoms in mid and apical hypertrophic cardiomyopathy. Echocar-diography 2009; 26: 922-933.
12. Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2011; 57: 2346-2355.
13. Efthimiadis GK, Parcharidou D, Pagourelias ED, Meditskou S, Spanos G, Hadjimiltiades S, et al. Prevalence and clinical outcomes of incidentally diagnosed hypertrophic cardiomyopathy. Am J Cardiol 2010; 105: 1445-1450.
14. Maron BJ, Gottdiener JS, Epstein SE. Patterns and signifcance of distribution of left ventricular hypertrophy in hypertrophic cardiomy-opathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981; 48: 418-428.
15. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and signifcance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995; 26: 1699-1708.
16. Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outfow tract pressure gradient in patients with hy-pertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19: 91-99.
17. Spiewak M, Malek LA, Misko J, Chojnowska L, Milosz B, Klopotowski M, et al. Comparison of different quantifcation methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Eur J Radiol 2010; 74: e149-e153, doi:10.1016/j.ejrad.2009.05.035 (accessed December 14, 2012).
18. Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J 2011; 75: 28-37.
19. Fighali S, Krajcer Z, Edelman S, Leachman RD. Progression of hy-pertrophic cardiomyopathy into a hypokinetic left ventricle: Higher incidence in patients with midventricular obstruction. J Am Coll Car-diol 1987; 9: 288-294.
20. De Gregorio C. Left ventricular dynamic obstruction by atypical papillary muscle morphology: Is this fnding so unusual in clinical practise? J Am Soc Echocardiogr 2007; 20: 100-101.
21. Nakamura T, Matsubara K, Furukawa K, Azuma A, Sugihara H, Katsume H, et al. Diastolic paradoxic jet fow in patients with hyper-trophic cardiomyopathy: Evidence of concealed apical asynergy with cavity obliteration. J Am Coll Cardiol 1992; 19: 516-524.
22. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006; 367: 356-367.
23. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51: 1369-1374.
24. Gerstenfeld EP. Hypertrophic cardiomyopathy with midventricular obstruction: Another substrate for ventricular tachycardia? J Cardio-vasc Electrophysiol 2010; 21: 1000-1001.
25. Maron BJ. Risk stratifcation and role of implantable defbrillators for prevention of sudden death in patients with hypertrophic cardio-myopathy. Circ J 2010; 74: 2271-2282.
26. Sherrid MV, Arabadjian M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis 2012; 54: 483-492.
27. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45: 1251-1258.